Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Ramesh R. Boinpally"'
Autor:
Abhijeet Jakate, Matthew Butler, Marissa F. Dockendorf, Wendy Ankrom, Ramesh R. Boinpally, Antonia Periclou
Publikováno v:
Cephalalgia Reports, Vol 4 (2021)
Background: Ubrogepant is metabolized by cytochrome P450 3A4 (CYP3A4) and is a P-glycoprotein (P-gp) substrate. Objective: To assess effects of multiple-dose moderate-strong CYP3A4 and strong P-gp inhibitors and inducers on ubrogepant pharmacokinetic
Autor:
Marie-Helene Vallee, Ramesh R. Boinpally, Marissa F. Dockendorf, Wendy Ankrom, Jialin Xu, K Chris Min, Danielle Armas
Publikováno v:
Journal of Clinical Pharmacology
The incidence of migraine is higher among women than men and peaks during the reproductive years, when contraceptive medication use is common. Atogepant, a potent, selective antagonist of the calcitonin gene‒related peptide receptor—in developmen
Autor:
Aspandiar G. Katki, Raymond W. Klecker, Ralph E. Parchment, S. Percy Ivy, Ramesh R. Boinpally, Jerry M. Collins, Patricia LoRusso, Lawrence W. Anderson
Publikováno v:
Cancer Chemotherapy and Pharmacology. 56:351-357
As part of an ongoing phase 1 study, we studied the excretion of XK469 and its metabolism in patients and in vitro. Five primary metabolites were identified by HPLC/MS/MS. An oxidized product formed by cytosolic aldehyde oxidase was the predominant s
Autor:
Ralph E. Parchment, Ramesh R. Boinpally, Maha Hussain, Ulka N. Vaishampayan, Lance K. Heilbrun, James A. Zwiebel, Patricia LoRusso, Vikash Jain
Publikováno v:
Investigational New Drugs. 23:179-185
Purpose: Fenretinide, a synthetic form of retinoid, induced apoptosis even in chemotherapy resistant cell lines. A phase II study was hence conducted to evaluate toxicity and efficacy of fenretinide in metastatic renal cancer. Methods: Eligibility in
Publikováno v:
Cancer Chemotherapy and Pharmacology. 55:404-407
To determine the oral bioavailability of R-XK469, a water-soluble investigational anticancer agent undergoing phase I clinical trials as an intravenous product.R-XK469 was administered to two groups of catheterized Sprague-Dawley rats via the oral an
Autor:
Srinivasu Poondru, Pratap Anne, Bhaskara R. Jasti, Gopinath Devraj, Ramesh R. Boinpally, Sen-Lin Zhou
Publikováno v:
International Journal of Pharmaceutics. 274:185-190
Site-specific immunosuppression with topical cyclosporin A (CsA) has broad clinical implications in the treatment of skin disorders like psoriasis, pyoderma gangrenosum, lichen planus, cutaneous graft-versus-host disease and contact hypersensitivity
Autor:
Shirish M. Gadgeel, Pamela DeLuca, Lance K. Heilbrun, Richard Wiegand, Amin M. Alousi, Ralph E. Parchment, A. Wozniak, Ramesh R. Boinpally, Patricia LoRusso
Publikováno v:
Investigational new drugs. 25(2)
Purpose: XK469, a member of the quinoxaline family of antitumor agents, is believed to be unique in its ability to selectively target topoisomerase IIβ. Based on encouraging pre-clinical data, a phase I trial was conducted to determine the dose limi
Autor:
Dimitrios Colevas, Richard Wiegand, Lance K. Heilbrun, Ralph E. Parchment, Vikas Jain, Ramesh R. Boinpally, Antoinette J. Wozniak, Patricia LoRusso, Marvin B. Cohen, Shirish M. Gadgeel
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(17)
Purpose: BMS-247550 is a semisynthetic derivative of epothilone B with mechanism of action analogous to paclitaxel. It has shown impressive antitumor activity in preclinical studies including in taxane-resistant models. We conducted a phase I trial,
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 56(3)
Skin penetration of topically applied diclofenac is important for the treatment of rheumatic diseases and actinic keratoses. We have studied the permeation of diclofenac across human cadaver epidermis in-vitro from four lecithin vesicle formulations
Autor:
Lance K. Heilbrun, Bruce G. Redman, Mark M. Zalupski, Ramesh R. Boinpally, Richard Wiegand, Antoinette J. Wozniak, Ralph E. Parchment, Patricia LoRusso, Shirish M. Gadgeel, Vikash Jain
Publikováno v:
Investigational new drugs. 21(1)
The spicamycin derivative KRN5500 was considered as a potential anti-cancer agent based on in vitro and preclinical studies. A Phase I study involving 24 cancer patients in whom tumors were refractory to all other conventional therapies was conducted